Tuesday, June 15, 2021

MANGALAM | Potential Performer | Stock Analysis and Price Outlook


Mangalam Drugs and Organics Limited 

CMP  138

➽  Mangalam Drugs and Organics Limited is an India-based company engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates. The Companys segments include bulk drugs, and chemicals and others.

➽ Key Stat

Promoters pledge remained unchanged at 33.57% of holdings in Mar 2021 qtr.

Promoters holding remains unchanged at 50.53% in Mar 2021 qtr

Institutional Investors holding remains unchanged at 0.01% in Mar 2021 qtr

High Piotroski Score - Companies with strong financials

Strong Annual EPS Growth

Company with Low Debt

Annual Net Profits improving for last 2 years

Recent Results : Growth in Operating Profit with increase in operating margins (YoY)

Strong Momentum: Price above short, medium and long term moving averages

MCL| Stock Analysis And Price Outlook

Financial Data Highlights

Market Cap207.11
Book Value/ Share82.679
Enterprise Value37.96
Revenue TTM380.14
Gross Profit TTM128.36
Revenue /Share TTM240.15

Key Profit & Loss Data

Net Inc27.9763.15 %
Ops Income44.1270.75 %
Revenue380.1469.05 %
Ops Expense336.0226.00 %
PBT39.5266.26 %
Gross Profit128.3687.76 %
Div Paid-2.6765.84 %

IEX | Stock Analysis And Price Outlook

 Technical & Price Outlook

mangalam stock share price chart,  finvestonline.com

Strong Performer: Stock with good financial performance alongside good to expensive valuation.

Bullish Momentum - Above Short, Medium and Long Term Moving Averages

Strong price rise supported with good volume.

A fresh breakout seen in today's session.

Long position can be made for the potential level of 158 in short term and 174 in mid term.

BRNL | Potential Outperformer | Stock Price Outlook

Thanks for your Precious Time.

Finvest Online
Telegram  :  https://t.me/finvestonlineChat

Disclaimer- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader,user and company that are mention on this website.  Please remember that this is a blog, and you do not need to agree with anything I write.We are not SEBI registered financial advisor or analyst.

No comments:

Post a Comment